Posts by Aditya Bardia, MD, MPH
-
Case Report: Genomic Testing Identifies NTRK Fusions in Patient With Refractory Metastatic Breast Cancer
Arielle J. Medford MD, Aditya Bardia, MD, MPH and colleagues present the case of a woman with metastatic triple-negative breast cancer with secretory features who had disease progression on multiple lines of therapy but responded rapidly and dramatically to larotrectinib after two NTRK fusions were identified.
-
Cell-Free DNA Assay Can Identify Microsatellite Instability–High Status in Advanced Breast Cancer
Neelima Vidula, MD, Dejan Juric, MD, Aditya Bardia, MD, MPH and colleagues from multiple centers in the U.S. have demonstrated that plasma-based genotyping ("liquid biopsy") can identify microsatellite instability–high status in patients with metastatic breast cancer.
-
ASCENT Trial: Sacituzumab Govitecan Has Survival Benefit in Metastatic Triple-negative Breast Cancer
Aditya Bardia, MD, MPH, is the first author of the report of the phase 3 ASCENT trial, which showed a significant survival benefit for sacituzumab govitecan compared with standard chemotherapy in patients with relapsed/refractory metastatic triple-negative breast cancer.
-
Novel Mechanism of Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer Identified by Mass General Researchers
Aditya Bardia, MD, MPH, Leif W. Ellisen, MD, PhD, and colleagues discovered that molecular alterations in both the antibody binding target and the payload target can potentially induce resistance to antibody–drug conjugates, a finding that has implications for the therapeutic sequencing of these agents.
-
Sacituzumab Govitecan-hziy Effective for Heavily Pretreated Metastatic Triple-Negative Breast Cancer
Aditya Bardia, MD, MPH, of the Cancer Center, and colleagues conducted the trial that led to accelerated approval of sacituzumab govitecan-hziy, an antibody–drug conjugate, for relapsed/refractory metastatic triple-negative breast cancer.
Biography
Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
